FDA advisors green-light Pfizer boosters for folks 65+ and at-risk teams

Vials with COVID-19 Vaccine labels showing logos of pharmaceutical company Pfizer and German biotechnology company BioNTech.

Enlarge / Vials with COVID-19 Vaccine labels exhibiting logos of pharmaceutical firm Pfizer and German biotechnology firm BioNTech. (credit score: Getty | Photonews)

A committee of impartial advisors for the Meals and Drug Administration has voted unanimously (18 to 0) in favor of authorizing a booster dose of the Pfizer/BioNTech COVID-19 vaccine for folks aged 65 and older, in addition to folks at excessive threat based mostly on an underlying medical situation and/or occupational publicity (e.g., healthcare staff). The booster doses are really helpful to be given no less than six months after completion of the first two doses.

If the FDA strikes ahead with the advisory committee’s suggestion—which it seemingly will—boosters can be provided to these two teams based mostly on an Emergency Use Authorization.

Previous to voting in favor of authorization for the 2 teams, the committee rejected the concept of approving boosters for all folks ages 16 and up with a convincing vote of 16 to 2 in opposition to.

Learn 18 remaining paragraphs | Feedback

Related Posts

Leave a Reply

Your email address will not be published.